AGILENT TECHNOLOGIES, INC（A）の決算・業績分析
AGILENT TECHNOLOGIES, INCの2025年有価証券報告書をAI分析。売上高$6.9B(+6.7%)。営業利益$1.5B。Health Care。
目次
AGILENT TECHNOLOGIES, INCの2025年度 業績サマリー
AGILENT TECHNOLOGIES, INC（証券コード: A）の2025年度決算・業績分析。売上高は$6.9B（前年比+6.7%）。営業利益は$1.5B（前年比-0.6%）。純利益は$1.3B（前年比+1.1%）。有価証券報告書を基に、業績変化の要因・リスク・見通し・セグメント構成を AI が分析しました。
AGILENT TECHNOLOGIES, INCの2024年度 注目ポイント
※ 直近の2025年度XBRLデータは取込済みですが、AI分析は2024年度の10-Kを対象としています。
- Revenue grew 8.4% YoY to $6.8B (XBRL), driven by Agilent CrossLab's 5% increase (10-K).
- Operating income surged 20.1% YoY to $1.6B with a robust 23.6% margin (XBRL).
- Net debt to EBITDA stood at 0.9x (XBRL), reflecting strong financial health despite $1.7B net debt (XBRL).
- Shareholder returns totaled $1.4B via $1.1B share repurchases and $250M dividends (XBRL).
- R&D investment reached $467M (XBRL), supporting innovation in application-focused solutions (10-K).
AGILENT TECHNOLOGIES, INCの売上高変化の要因
- •FY2024 revenue reached $6.8B (+8.4% YoY) (XBRL). Growth was driven by Agilent CrossLab's 5% increase (10-K), while Life Sciences & Applied Markets and Diagnostics & Genomics segments declined due to customer capital expenditure pressures (10-K). Historical time series shows revenue growth from $4.9B (2020) to $6.8B (2024) (XBRL). Segment-specific revenue figures are not disclosed in XBRL data (N/A).
AGILENT TECHNOLOGIES, INCの営業利益変化の要因
- •Operating income rose 20.1% YoY to $1.6B (23.6% margin) (XBRL), driven by cost management and Agilent CrossLab's performance (10-K). Net income increased 3.6% YoY to $1.3B (18.3% margin) (XBRL). EBITDA reached $1.9B (28.3%) (XBRL), reflecting efficient operations. R&D expense was $467M (XBRL), supporting long-term innovation.
AGILENT TECHNOLOGIES, INCの事業リスクと対応
Economic downturns may reduce demand, delay shipments, and increase inventory risks (10-K).
Market volatility could harm revenue, liquidity, and profitability due to unpredictable customer orders (10-K).
Failure to innovate risks product obsolescence and reduced revenue (10-K).
International operations face currency fluctuations, geopolitical risks, and supply chain disruptions (10-K).
Collaboration with pharmaceutical customers risks drug program cancellations due to clinical trial failures (10-K).
AGILENT TECHNOLOGIES, INCの今後の見通し・業績予想
AGILENT TECHNOLOGIES, INCの事業内容
Agilent Technologies operates in life sciences, diagnostics, and applied chemical markets, generating revenue through instruments, software, services, and consumables (10-K). Key segments include Life Sciences & Applied Markets, Diagnostics & Genomics, and Agilent CrossLab (10-K). Competitive advantages include vendor-neutral consumables, high operating margins (23.6%) (XBRL), and a global workforce of ~17,900 (10-K). The company emphasizes application-focused solutions and extensive services (10-K).
AGILENT TECHNOLOGIES, INCのAI業績分析レポート（2024年度）
Agilent Technologies, Inc. FY2024 Annual Report Analysis
Highlights
Business Overview
Agilent Technologies operates in life sciences, diagnostics, and applied chemical markets, generating revenue through instruments, software, services, and consumables (10-K). Key segments include Life Sciences & Applied Markets, Diagnostics & Genomics, and Agilent CrossLab (10-K). Competitive advantages include vendor-neutral consumables, high operating margins (23.6%) (XBRL), and a global workforce of ~17,900 (10-K). The company emphasizes application-focused solutions and extensive services (10-K).
Revenue Analysis
FY2024 revenue reached $6.8B (+8.4% YoY) (XBRL). Growth was driven by Agilent CrossLab's 5% increase (10-K), while Life Sciences & Applied Markets and Diagnostics & Genomics segments declined due to customer capital expenditure pressures (10-K). Historical time series shows revenue growth from $4.9B (2020) to $6.8B (2024) (XBRL). Segment-specific revenue figures are not disclosed in XBRL data (N/A).
Profitability Analysis
Operating income rose 20.1% YoY to $1.6B (23.6% margin) (XBRL), driven by cost management and Agilent CrossLab's performance (10-K). Net income increased 3.6% YoY to $1.3B (18.3% margin) (XBRL). EBITDA reached $1.9B (28.3%) (XBRL), reflecting efficient operations. R&D expense was $467M (XBRL), supporting long-term innovation.
Balance Sheet Analysis
Equity ratio was 54.3% (XBRL), with long-term debt at $2.7B and net debt at $1.7B (0.9x EBITDA) (XBRL). Current ratio stood at 2.61x (XBRL), indicating strong liquidity. Cash reserves totaled $1.1B (XBRL). ROE was 21.4% (XBRL), and ROA was 11.7% (XBRL), reflecting efficient asset utilization.
Cash Flow Analysis
Operating cash flow was $1.3B (XBRL), matching net income. Free cash flow (FCF) was $1.0B (XBRL), calculated as $1.3B OCF minus $291M CapEx (XBRL). Investing activities included a $915M acquisition of BIOVECTRA (10-K). Financing activities totaled -$1.4B (XBRL), driven by $1.1B share repurchases and $250M dividends (XBRL).
Working Capital Analysis
Cash conversion cycle (CCC) was 140 days (XBRL), with receivables at 69 days, inventory at 120 days, and payables at 49 days (XBRL).
Risks
Outlook
Management highlights customer capital expenditure pressures, the BIOVECTRA acquisition, and the new segment structure as key trends impacting future results (10-K). No explicit forward-looking guidance is provided (N/A).
Health Careの企業一覧
AGILENT TECHNOLOGIES, INCと同じ「Health Care」セクターの企業